# DIBBS #SPE2DP-27-T-0212

DLA procurement of two bottles of TEMBEXA brincidofovir oral suspension

**Posted:** November 02, 2026
**Respond By:** November 09, 2026
**Identifier:** SPE2DP-27-T-0212
**NAICS:** 424210

DLA is seeking a small, rapid-delivery supply of **TEMBEXA (brincidofovir) oral suspension** for Walter Reed National Military Medical Center.
- **Government buyer:** Defense Logistics Agency (DLA), DLA Troop Support, Medical Supply Chain Pharm FSA; buyer contact: James Foggie.
- **Product and quantity:** 2 bottles of brincidofovir 10 mg/mL oral suspension (TEMBEXA), NSN 6505-01-735-0149.
  - Approved source: **Emergent Biodefense Operations Lans**; approved source part numbers NDC64678-0012-01 and NDC79622-0012-65.
- **Handling requirements:** Store at 20–25°C (68–77°F) at USP controlled room temperature, protect from freezing, and discard unused product 30 days after opening.
- **Delivery:** FOB destination to Walter Reed National Military Medical Center, required 20 days after order.

### Description

BRINCIDOFOVIR ORAL SUS (QTY: 2, NSN: 6505017350149, Purchase Request: 7018927942)

[View original listing](https://www.dibbs.bsm.dla.mil/rfq/rfqrec.aspx?sn=SPE2DP27T0212)